A panel of experts reviews key data updates in multiple myeloma from IMS [International Myeloma Society Annual Meeting] 2022 and other recent meetings and discusses how they can be best applied in clinical practice.
EP. 1: Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.
EP. 2: Available Induction Regimen Options for Patients with Transplant-Eligible NDMM
The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.
EP. 3: Recap: Recent Research in Multiple Myeloma
At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.
EP. 4: Evaluating MRD-Guided Therapy in Patients with NDMM
Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.
EP. 5: Assessing Response and Duration of Treatment in Transplant-Eligible NDMM
Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.
EP. 6: Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma
Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.
EP. 7: Selecting Frontline Treatment Regimens for Transplant-Ineligible MM
Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.
EP. 8: Data Updates in Transplant Ineligible NDMM
Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.
EP. 9: Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM
Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.
EP. 10: Defining Frail Patients in Multiple Myeloma
Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.
EP. 11: Treatment Options for Patients with Relapsed Multiple Myeloma
Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.
EP. 12: Bispecifics in Development for the Treatment of R/R MM
Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.
EP. 13: Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM
The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.
2 Commerce Drive Cranbury, NJ 08512